Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has extended its long-standing strategic collaboration with Bristol Myers Squibb through 2035. Previously, in 2021, the companies extended the research alliance through 2030. The expanded agreement broadens the scope of integrated services across the drug development lifecycle spanning discovery (chemistry, biology, drug metabolism and pharmacokinetics), translational sciences, pharmaceu...